Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - vinblastine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: water for injections; sodium chloride - used in the treatment of hodgkins' disease (stages iii and iv) in combination therapy (with adriamycin, bleomycin and dacarbazine as abvd) and in the treatment of advanced testicular carcinoma (with cisplatin and bleomycin). in the palliative treatment of lymphocytic lymphoma, histiocytic lymphoma, kaposi's sarcoma and histiocytosis x. advanced stages of mycosis fungoides. may be used in the treatment of choriocarcinoma resistant to other chemotherapeutic agents; carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: sulfuric acid; mannitol; water for injections; sodium hydroxide - vincristine sulfate is indicated in acute leukaemia - current practices of cancer chemotherapy involve the simultaneous use of several agents. for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. it is rarely possible to achieve equally good results with single agent treatment. thus vincristine sulfate is often chosen as part of polychemotherapy because of its unique clinical toxicity (neuropathy). see dosage and administration for possible increased toxicity when used in combination therapy. it has been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: water for injections; mannitol; sulfuric acid; sodium hydroxide - vincristine sulfate is indicated in acute leukaemia - current practices of cancer chemotherapy involve the simultaneous use of several agents. for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. it is rarely possible to achieve equally good results with single agent treatment. thus vincristine sulfate is often chosen as part of polychemotherapy because of its unique clinical toxicity (neuropathy). see dosage and administration for possible increased toxicity when used in combination therapy. it has been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma

United States - English - NLM (National Library of Medicine)

hospira, inc. - vincristine sulfate (unii: t5iro3534a) (vincristine - unii:5j49q6b70f) - vincristine sulfate injection is indicated in acute leukemia. vincristine sulfate injection has also been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non–hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and wilms' tumor. patients with the demyelinating form of charcot–marie–tooth syndrome should not be given vincristine sulfate injection. careful attention should be given to those conditions listed under warnings and precautions .

United States - English - NLM (National Library of Medicine)

hospira, inc. - vincristine sulfate (unii: t5iro3534a) (vincristine - unii:5j49q6b70f) - vincristine sulfate injection is indicated in acute leukemia. vincristine sulfate injection has also been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non–hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and wilms' tumor. patients with the demyelinating form of charcot–marie–tooth syndrome should not be given vincristine sulfate injection. careful attention should be given to those conditions listed under warnings and precautions .

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. none risk summary available data from randomized studies, case series, and reports of ephedrine sulfate use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.  however, there are clinical considerations (see clinical considerations) . in animal reproduction studies, decreased fetal survival and fetal body weights were observed in the presence of maternal toxicity after normotensive pregnant rats were administered 60 mg/kg intravenous ephedrine sulfate (12 times the maximum recommended human dose (mrhd) of 50 mg/day). no malformations or embryofetal adverse effects were observed when pregnant rats or rabbits were treated with intravenous bolus doses of ephedrine sulfate during organogenesis at doses 1.9 and 7.7 times the mrhd, respectively (see data) .  the estimated background risk of major b

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; water for injections; sodium hydroxide; sulfuric acid - vincristine is used primarily in the treatment of acute leukaemia, usually as a component of various chemotherapeutic regimens. it has also been used as part of combination therapy in the treatment of hodgkin's disease, non-hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma of the lung and gynaecological tumours of childhood. vincristine may be useful in patients with true idiopathic thrombocytopenic purpura resistant to the usual treatment, but not recommended as primary treatment for this disorder

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - vinblastine sulfate (unii: n00w22yo2b) (vinblastine - unii:5v9klz54cy) - vinblastine sulfate 1 mg in 1 ml - vinblastine sulfate injection is indicated in the palliative treatment of the following: i. frequently responsive malignancies - generalized hodgkin’s disease (stages iii and iv, ann arbor modification of rye staging system) - lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) - histiocytic lymphoma - mycosis fungoides (advanced stages) - advanced carcinoma of the testis - kaposi’s sarcoma - letterer-siwe disease (histiocytosis x) ii. less frequently responsive malignancies - choriocarcinoma resistant to other chemotherapeutic agents - carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents.  for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected.  therefore, although vinblastine

Malta - English - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - vincristine sulfate - solution for infusion or injection - vincristine sulfate 1 mg/ml - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - follitropin delta, quantity: 72 microgram - injection, solution - excipient ingredients: phenol; methionine; sodium sulfate decahydrate; dibasic sodium phosphate dodecahydrate; polysorbate 20; phosphoric acid; sodium hydroxide; water for injections - controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (art) such as an in vitro fertilisation (ivf) or intracytoplasmic sperm injection (icsi) cycle.